These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

173 related items for PubMed ID: 15888284

  • 1. Urine diacetylspermine as a novel tumour maker for pancreatobiliary carcinomas.
    Yamaguchi K, Nakamura M, Shirahane K, Konomi H, Torata N, Hamasaki N, Kawakita M, Tanaka M.
    Dig Liver Dis; 2005 Mar; 37(3):190-4. PubMed ID: 15888284
    [Abstract] [Full Text] [Related]

  • 2. [Urine diacetylspermine as a novel tumor marker for pancreatobiliary carcinomas].
    Yamaguchi K, Nagano M, Torada N, Hamasaki N, Kawakita M, Tanaka M.
    Rinsho Byori; 2004 Apr; 52(4):336-9. PubMed ID: 15164602
    [Abstract] [Full Text] [Related]

  • 3. [Urine diacetylspermine as a novel tumor marker].
    Yamaguchi K, Kaku T, Enjoji M, Kato M, Anai M, Kawakita M, Hamasaki N, Tanaka M.
    Rinsho Byori; 2005 Feb; 53(2):130-5. PubMed ID: 15796046
    [Abstract] [Full Text] [Related]

  • 4. N(1),N(12)-Diacetylspermine as a sensitive and specific novel marker for early- and late-stage colorectal and breast cancers.
    Hiramatsu K, Takahashi K, Yamaguchi T, Matsumoto H, Miyamoto H, Tanaka S, Tanaka C, Tamamori Y, Imajo M, Kawaguchi M, Toi M, Mori T, Kawakita M.
    Clin Cancer Res; 2005 Apr 15; 11(8):2986-90. PubMed ID: 15837752
    [Abstract] [Full Text] [Related]

  • 5. The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer.
    Ni XG, Bai XF, Mao YL, Shao YF, Wu JX, Shan Y, Wang CF, Wang J, Tian YT, Liu Q, Xu DK, Zhao P.
    Eur J Surg Oncol; 2005 Mar 15; 31(2):164-9. PubMed ID: 15698733
    [Abstract] [Full Text] [Related]

  • 6. Evaluating the utility of N1,N12-diacetylspermine and N1,N8-diacetylspermidine in urine as tumor markers for breast and colorectal cancers.
    Umemori Y, Ohe Y, Kuribayashi K, Tsuji N, Nishidate T, Kameshima H, Hirata K, Watanabe N.
    Clin Chim Acta; 2010 Dec 14; 411(23-24):1894-9. PubMed ID: 20655890
    [Abstract] [Full Text] [Related]

  • 7. Multivariate analysis of six serum tumor markers (CEA, CA 50, CA 242, TPA, TPS, TATI) and conventional laboratory tests in the diagnosis of hepatopancreatobiliary malignancy.
    Pasanen PA, Eskelinen M, Partanen K, Pikkarainen P, Penttilä I, Alhava E.
    Anticancer Res; 1995 Dec 14; 15(6B):2731-7. PubMed ID: 8669855
    [Abstract] [Full Text] [Related]

  • 8. The value of combined use of serum tumour markers and nuclear magnetic spectroscopy of plasma in the detection of pancreatic cancer among patients with jaundice or cholestasis: results from a prospective study.
    Pasanen PA, Kauppinen R, Eskelinen M, Partanen K, Pikkarainen P, Alhava E.
    Anticancer Res; 1993 Dec 14; 13(3):763-8. PubMed ID: 8317910
    [Abstract] [Full Text] [Related]

  • 9. Evaluation of the diagnostic value of serum tumor markers, and fecal k-ras and p53 gene mutations for pancreatic cancer.
    Wu X, Lu XH, Xu T, Qian JM, Zhao P, Guo XZ, Yang XO, Jiang WJ.
    Chin J Dig Dis; 2006 Dec 14; 7(3):170-4. PubMed ID: 16808798
    [Abstract] [Full Text] [Related]

  • 10. Are serum and biliary carcinoembryonic antigen and carbohydrate antigen19-9 determinations reliable for differentiation between benign and malignant biliary disease?
    Akdoğan M, Parlak E, Kayhan B, Balk M, Saydam G, Sahin B.
    Turk J Gastroenterol; 2003 Sep 14; 14(3):181-4. PubMed ID: 14655062
    [Abstract] [Full Text] [Related]

  • 11. Determination of N¹,N¹²-diacetylspermine in urine: a novel tumor marker.
    Kawakita M, Hiramatsu K, Yanagiya M, Doi Y, Kosaka M.
    Methods Mol Biol; 2011 Sep 14; 720():367-78. PubMed ID: 21318886
    [Abstract] [Full Text] [Related]

  • 12. CEA, CA 19-9 and CA 72-4 improve the diagnostic accuracy in gastrointestinal cancers.
    Carpelan-Holmström M, Louhimo J, Stenman UH, Alfthan H, Haglund C.
    Anticancer Res; 2002 Sep 14; 22(4):2311-6. PubMed ID: 12174919
    [Abstract] [Full Text] [Related]

  • 13. [Tumor markers for pancreatic and biliary tract cancer].
    Takezako Y, Okusaka T, Ueno H, Ikeda M, Morizane C, Najima M.
    Gan To Kagaku Ryoho; 2004 Sep 14; 31(9):1443-6. PubMed ID: 15446574
    [Abstract] [Full Text] [Related]

  • 14. Comparison of tumor marker CA 242 with CA 19-9 and carcinoembryonic antigen (CEA) in pancreatic cancer.
    Ozkan H, Kaya M, Cengiz A.
    Hepatogastroenterology; 2003 Sep 14; 50(53):1669-74. PubMed ID: 14571813
    [Abstract] [Full Text] [Related]

  • 15. Gallbladder bile tumor marker quantification for detection of pancreato-biliary malignancies.
    Brockmann J, Emparan C, Hernandez CA, Sulkowski U, Dietl KH, Menzel J, Wolters H, Glodny B, Senninger N.
    Anticancer Res; 2000 Sep 14; 20(6D):4941-7. PubMed ID: 11326643
    [Abstract] [Full Text] [Related]

  • 16. Clinical evaluation of tissue polypeptide antigen (TPA) in the diagnosis of pancreatic carcinoma.
    Pasanen PA, Eskelinen M, Partanen K, Pikkarainen P, Penttila I.
    Anticancer Res; 1993 Sep 14; 13(5C):1883-7. PubMed ID: 8267397
    [Abstract] [Full Text] [Related]

  • 17. Detection of serum tumor markers in the diagnosis and treatment of patients with pancreatic cancer.
    Jiang XT, Tao HQ, Zou SC.
    Hepatobiliary Pancreat Dis Int; 2004 Aug 14; 3(3):464-8. PubMed ID: 15313690
    [Abstract] [Full Text] [Related]

  • 18. Preoperative serum carcinoembryonic antigen and carbohydrate antigen 19-9 levels for the evaluation of curability and resectability in patients with pancreatic adenocarcinoma.
    Fujioka S, Misawa T, Okamoto T, Gocho T, Futagawa Y, Ishida Y, Yanaga K.
    J Hepatobiliary Pancreat Surg; 2007 Aug 14; 14(6):539-44. PubMed ID: 18040617
    [Abstract] [Full Text] [Related]

  • 19. Serum levels of IGF-I and IGFBP-III and their relation with carcinoembryonic antigen and carbohydrate antigen 19-9 in cases of esophageal cancer.
    Yilmaz O, Eroglu A, Dag E, Karaoglanoglu N, Yilmaz A.
    Int J Clin Pract; 2006 Dec 14; 60(12):1604-8. PubMed ID: 16704680
    [Abstract] [Full Text] [Related]

  • 20. The diagnostic importance of CEA and CA 19-9 for the early diagnosis of pancreatic carcinoma.
    Nazli O, Bozdag AD, Tansug T, Kir R, Kaymak E.
    Hepatogastroenterology; 2000 Dec 14; 47(36):1750-2. PubMed ID: 11149048
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.